RxDoctor Payments Data

Amanda Nakashian

Women's Health · Dyer, INNPI 1558783019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,820 and has fallen 73.0% since, to $492 in 2025. Among women's health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,564in general payments, 2019–2025

Across 347 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$459
  • Johnson & Johnson$425
  • Astellas Pharma US Inc$402
  • Merck$388
  • Seagen Inc.$371
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$7,41498%
  • Education$1502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,564 in reported general payments places this provider in the 95th percentile of 142 women's health providers in Indiana.

See all women's health providers in Indiana

Medicare billing

Part B allowed, 2024
$15,850
Medicare patients
91
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated26$8,305
Fluconazole19$327
Nystatin15$189
Clobetasol Propionate15$181
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$142
Estradiol12$82
Pantoprazole Sodium11$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$84$8,30526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 women's health providers in Indiana.

Other women's health in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →